Date of Award
7-29-2022
Document Type
Thesis
Degree Name
Master of Science (MS)
Department
Chemistry
First Advisor
Jerry Darsey
Second Advisor
Rupak Pathak
Abstract
Breast cancer is currently the most prevalent form of cancer in women worldwide and the second most prevalent in the United States. Chemotherapy is a major treatment modality for breast cancer, however, chemotherapy causes severe side effects that significantly lowers the patient’s quality of life. Mevalonate pathway inhibitors have historically been implicated in the treatment of cardiovascular disease but have more recently garnered interest as potential anticancer agents with minimal side effects. Here, we report for the first time to our knowledge that mevalonate pathway inhibitors and chemotherapeutic drugs synergistically attenuate human breast cancer cell (MCF-7) proliferation in culture. We observed that combined treatment reduced MCF-7 cell proliferation and colony forming ability to a greater extent than the singular treatments. These findings represent a valuable alternative treatment strategy, which require further validation in pre-clinical and clinical studies.
Recommended Citation
Moore, Cole, "Mevalonate Pathway Inhibitors Potentiate the Efficacy of Chemotherapeutic Drugs to Limit Breast Cancer Cell Growth" (2022). Theses and Dissertations. 1095.
https://research.ualr.edu/etd/1095
